YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (HK:1558) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has entered a licensing agreement with Shenyang Sunshine Pharmaceutical Co., Ltd. to commercialize Clifutinib Besylate in China. The agreement involves an upfront payment of RMB 60 million, with additional milestone payments contingent on certain achievements. This strategic move aims to leverage Clifutinib’s potential in the Chinese market, while the company retains rights outside of China.
For further insights into HK:1558 stock, check out TipRanks’ Stock Analysis page.